Galmed Pharmaceuticals (GLMD) Gains from Investment Securities (2013 - 2025)
Galmed Pharmaceuticals (GLMD) recorded quarterly Gains from Investment Securities of $270.0 in Q4 2025, little changed quarter-over-quarter from $270.0 in Q4 2024, and little changed on a YoY basis from $270.0 in Q4 2024.
Galmed Pharmaceuticals (GLMD) Gains from Investment Securities (2013 - 2025) Analysis & Trends
Galmed Pharmaceuticals' Gains from Investment Securities history runs 12 years deep, the most recent figure standing at $270.0 for Q4 2025.
- In Q4 2025, Gains from Investment Securities changed 0.0% year-over-year to $270.0; the TTM figure through Dec 2025 stood at $270.0 (changed 0.0% YoY), while the FY2025 annual figure was $270.0, changed 0.0% from the prior year.
- Gains from Investment Securities was $270.0 for Q4 2025 at Galmed Pharmaceuticals, roughly flat from $270.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $189390.0 in Q4 2021 to a low of -$1.2 million in Q4 2022.
- Historically, Gains from Investment Securities has averaged -$117007.0 across 5 years, with a median of $270.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities tumbled 748.4% in 2022, then surged 110.18% in 2023.
- A 5-year view of Gains from Investment Securities shows it stood at $189390.0 in 2021, then tumbled by 748.4% to -$1.2 million in 2022, then surged by 110.18% to $125000.0 in 2023, then tumbled by 99.78% to $270.0 in 2024, then changed by 0.0% to $270.0 in 2025.
- The last three Gains from Investment Securities figures came in at $270.0 (Q4 2025), $270.0 (Q4 2024), and $1000.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Galmed Pharmaceuticals | 2.48 Mn | -1.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 270.00 |
| Dec 31, 2025 | 270.00 |
| Dec 31, 2024 | 270.00 |
| Dec 31, 2024 | 270.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 125,000.00 |
| Dec 31, 2023 | 125,000.00 |
| Sep 30, 2023 | -55,000.00 |
| Sep 30, 2023 | -55,000.00 |
| Mar 31, 2023 | -100,000.00 |
| Mar 31, 2023 | -100,000.00 |
| Dec 31, 2022 | -1.23 Mn |
| Dec 31, 2022 | -1.23 Mn |
| Sep 30, 2022 | -106,000.00 |
| Sep 30, 2022 | -106,000.00 |
| Dec 31, 2021 | 189,390.00 |
| Dec 31, 2021 | 189,390.00 |
| Mar 31, 2021 | 3,000.00 |
| Mar 31, 2021 | 3,000.00 |